Skip to Content
Merck
  • Pervasive seizures caused by hypoxic-ischemic encephalopathy: treatment with intravenous paraldehyde.

Pervasive seizures caused by hypoxic-ischemic encephalopathy: treatment with intravenous paraldehyde.

Journal of child neurology (2002-01-12)
D L Armstrong, M R Battin
ABSTRACT

Seizures are commonly associated with hypoxic-ischemic encephalopathy. Although the majority of cases are controlled with first- or second-line therapy, others develop pervasive seizures, requiring multiple anticonvulsants. To provide data on the incidence of seizures and response to anticonvulsant therapies, a cohort of 90 term infants with hypoxic-ischemic encephalopathy treated at our institution between January 1, 1995, and July 1, 1999, was reviewed. Of the 60 infants who developed seizures, 59 received phenobarbital initially; in 29 cases, the seizures resolved. The remaining 30 infants received phenytoin as a second-line anticonvulsant, and seizures stopped in 10 cases. The 20 infants with ongoing pervasive seizures were treated with intravenous paraldehyde.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Paraldehyde, ≥97.0% (GC)
Sigma-Aldrich
Paraldehyde, ≥97%
Sigma-Aldrich
Paraldehyde, Arxada quality, ≥99.5% (GC)